Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?

Milena Gusella1 | Felice Pasini2 | Barbara Corso3 | Laura Bertoloso1 | Giovanni De Rosa4 | Cristina Falci5 | Yasmina Modena1 | Carmen Barile1 | Donatella Da Corte Z6 | AnnaPaola Fracon2 | Silvia Toso7 | Elisabetta Cretella8 | Antonella Brunello9 | Caterina Modonesi10 | Romana Segati11 | Cristina Oliani1 | Nadia Minicuci3 | Roberto Padrini4 | for the Italian TAM Group†

1Oncology Unit, AULSS5 Polesana, Rovigo, Italy
2Oncology Unit, Casa di Cura Pederzoli, Peschiera del Garda, Italy
3National Research Council, Neuroscience Institute, Padova, Italy
4Clinical Pharmacology Unit of the Department of Medicine (DIMED), University of Padova, Padova, Italy
5Oncology Unit 2, Istituto Oncologico Veneto (IOV), IRCCS Padova, Padova, Italy
6Oncology Unit, Ospedale di Belluno, Belluno, Italy
7Oncology Unit, Ospedale di Adria, Polesana, Italy
8Oncology Unit, Ospedale di Bolzano, Bolzano, Italy
9Oncology Unit 1, Istituto Oncologico Veneto (IOV), IRCCS Padova, Padova, Italy
10Oncology Unit, Ospedali Riuniti Padova Sud, Padova, Italy
11Oncology Unit, Ospedale di Feltre, Feltre, Italy

Correspondence
Barbara Corso, National Research Council, Neuroscience Institute, Via Gallucci, 16, 35121 Padova, Italy.
Email: barbara.corso@in.cnr.it

Abstract
In previous studies, steady-state Z-endoxifen plasma concentrations (ENDOss) correlated with relapse-free survival in women on tamoxifen (TAM) treatment for breast cancer. ENDOss also correlated significantly with CYP2D6 genotype (activity score) and CYP2D6 phenotype (dextromethorphan test). Our aim was to ascertain which method for assessing CYP2D6 activity is more reliable in predicting ENDOss. The study concerned 203 Caucasian women on tamoxifen-adjuvant therapy (20 mg q.d.). Before starting treatment, CYP2D6 was genotyped (and activity scores computed), and the urinary log(dextromethorphan/dextrorphan) ratio [log(DM/DX)] was calculated after 15 mg of oral dextromethorphan. Plasma concentrations of TAM, N-desmethyl-tamoxifen (ND-TAM), Z-4OH-tamoxifen (4OH-TAM) and ENDO were assayed 1, 4, and 8 months after first administering TAM. Multivariable regression analysis was used to identify the clinical and laboratory variables predicting log-transformed ENDOss (log-ENDOss). Genotype-derived CYP2D6 phenotypes (PM, IM, NM, EM) and log(DM/DX) correlated independently with log-ENDOss. Genotype-phenotype concordance was almost complete only for poor metabolizers, whereas it emerged that 34% of intermediate, normal, and ultrarapid metabolizers were classified differently based on log(DM/DX). Multivariable regression analysis selected log(DM/DX) as the best predictor, with patients’ age, weak inhibitor use, and CYP2D6 phenotype decreasingly important: log-ENDOss = 0.162 - log(DM/DX) × 0.170 + age × 0.0063 - weak inhibitor use × 0.250 + IM × 0.105 + (NM + UM
1 | INTRODUCTION

Tamoxifen (TAM) is a selective estrogen receptor antagonist used as adjuvant therapy to prevent estrogen-receptor-positive breast cancer recurrence. TAM is de facto a prodrug because its anti-estrogen activity is 30-100 times less than that of its metabolites Z-4OH-tamoxifen (4OH-TAM) and Z-endoxifen (ENDO). END0 is considered the most effective metabolite in vivo, with plasma concentrations 5-10 times higher than 4OH-TAM. Two well-powered trials found END0 plasma concentrations correlated with recurrence risk. Madlensky et al reported that women with END0 concentrations > 5.97 ng ml⁻¹ had a 30% lower relative risk of breast cancer recurrence. Saladores et al found END0 levels < 5.2 ng ml⁻¹ (< 14 nM) associated with a shorter relapse-free survival (RFS) compared with > 13.0 ng ml⁻¹ (> 35 nM). Hence the suggestion that monitoring END0 concentrations can be used to individualize adjuvant TAM therapy.

An alternative strategy involves measuring predictors of steady-state END0 levels (END0ss) before starting TAM therapy. While several enzymes contribute to END0 formation (CYP3A4/5, CYP2C9, CYP2C19, CYP1A2) and elimination (UGTs, SULTs), the main metabolic pathway is END0 formation from N-desmethyl-tamoxifen (ND-TAM) by the cytochrome CYP2D6 (Figure 1). CYP2D6 activity has been estimated indirectly by combining the several CYP2D6 allelic variants with a different gene expression, or calculated directly from the dextromethorphan (DM)/dextrorphan (DX) urinary metabolic ratio [log(DM/DX)]. Both methods can predict END0ss. CYP2D6 phenotyping is considered superior to genotyping because non-genetic factors like age, drug-drug interactions, or co-morbidities can affect phenotype (phenoconversion phenomenon), but the two methods’ performance had yet to be compared directly.

Our primary aim was to ascertain which method - CYP2D6 genotyping or phenotyping - can predict END0ss more accurately. The findings presented here are part of an ongoing prospective trial (TAM study) to correlate END0ss with breast cancer recurrence.

What is already known about this subject
- Endoxifen is the active metabolite of tamoxifen, which is responsible for most of its anti-estrogen activity.
- Steady-state endoxifen concentrations (END0ss) > 5.97 ng ml⁻¹ correlate with relapse-free survival of breast cancer patients.
- CYP2D6 phenotype inferred from CYP2D6 genotype and dextromethorphan/dextrorphan metabolic ratio [log (DM/DX)] correlate with END0ss.

What this study adds
- An algorithm including log(DM/DX), patient’s age and weak inhibitor use predicts 48% of log-END0ss variability.
- CYP2D6 phenotypes have a weaker predictive power than log(DM/DX) ($R^2 = 0.41$).
- The model based on log(DM/DX) may identify patients who will have END0ss < 5.97 ng ml⁻¹, and consequently require a higher starting dose of tamoxifen.

2 | METHODS

2.1 | Patients and study design

This study concerned 203 Caucasian women with estrogen-receptor-positive breast cancer (stage IA 67.2%, IIA 23.2%, IIB 6.8%, and IIIA 2.8%) on TAM adjuvant therapy (20 mg q.d.) involved in a trial enrolling patients from 20 oncology units in Northern Italy.

Before starting TAM, blood samples were drawn for CYP2D6 genotyping. CYP2D6 phenotyping was done as follows: 15 mg of oral dextromethorphan were administered at 10 PM, then urine was collected overnight until 8 AM, when a sample was frozen at −20°C until analysis of DM and DX concentrations (see below).

One, 4, and 8 months after starting TAM, blood was sampled before a drug dose to assay plasma concentrations of TAM, ND-TAM, 4OH-TAM, and END0. All other routine procedures were completed according to local clinical practice.

The study protocol was approved by the Ethics Committee of Rovigo Hospital (Italy) and all participants gave their written informed consent.
2.2 | Plasma assay of ENDO, 4OH-TAM, ND-TAM, and TAM

Tamoxifen and its metabolites were analyzed in patients’ plasma using a validated high-performance liquid chromatography (HPLC) method, with partial adaptations. Briefly, blood was centrifuged within an hour of sampling and plasma was stored at −20°C until analysis. One mL of plasma was alkalinized with 1 ml-glycine/NaOH buffer (1M, pH: 11.3) and extracted with 7 ml of hexane/2-propanol (95:5, v:v). After centrifugation, the supernatant was analyzed. One mL of plasma was alkalinized with 1 ml-glycine/NaOH buffer to obtain concentrations in the range of 0.25-10 μg ml-1. Within this range, the curves of the activity scores for each allele (AS) was translated into a full gene deletion, accounting for most of the clinically significant variants of CYP2D6 in Caucasian populations. Genotyping was conducted using PCR/RLFP-based methods for CYP2D6*3 (2549 A del, rs35742686), CYP2D6*4 (1846G>A, rs3892097), CYP2D6*6 (1707T del, rs5030655), CYP2D6*9 (2615_2617del AAG, rs5030656), CYP2D6*10 (100C>T, rs1065852), with digestion by MspI, BstN1, BtsI, MboII, and HphI, respectively, for the following CYP2D6 phenotypes: ultrarapid metabolizers (UM), AS > 2.25; normal metabolizers (NM), 1.25 ≤ AS ≤ 2.25; intermediate metabolizers (IM), 0 < AS < 1.25; poor metabolizers (PM), AS = 0.

2.3 | CYP2D6 genotyping procedure

Germline DNA was isolated from blood using Wizard Genomic DNA Purification Kit (Promega) according to the manufacturer’s recommendations.

Samples were analyzed for six polymorphisms and a full gene deletion, accounting for most of the clinically significant variants of CYP2D6 in Caucasian populations. Genotyping was conducted using PCR/RLFP-based methods for CYP2D6*3 (2549 A del, rs35742686), CYP2D6*4 (1846G>A, rs3892097), CYP2D6*6 (1707T del, rs5030655), CYP2D6*9 (2615_2617del AAG, rs5030656), CYP2D6*10 (100C>T, rs1065852), with digestion by MspI, BstN1, BtsI, MboII, and HphI, respectively, for the following CYP2D6 phenotypes: ultrarapid metabolizers (UM), AS > 2.25; normal metabolizers (NM), 1.25 ≤ AS ≤ 2.25; intermediate metabolizers (IM), 0 < AS < 1.25; poor metabolizers (PM), AS = 0.

2.4 | Urinary DM and DX assay

Urinary DM and DX were tested using HPLC according to Flores-Péres et al.22 with slight modifications. Before the extraction procedure, 0.5 ml of urine was hydrolyzed overnight at 37°C by adding 0.5 ml of a solution of β-glucuronidase (2000 U ml-1) in acetate buffer (pH 5). This step was necessary because most DX in urine is in the form of glucuronide. Then 500 ml of hydrolysate were spiked with 25 μl of a 0.1 mg ml-1 levallophan solution (as internal standard) and 500 μl of carbonate buffer (pH 9.2) were added. Extraction was done with 3.5 ml of a hexane-butanol mixture (95:5, v/v) in a shaker rotated for 10 minutes. After centrifugation at 855 g for 5 minutes, the organic phase was separated and evaporated to dryness at 55°C under gentle nitrogen stream. The residue was reconstituted with 1 ml of mobile phase and 10 μl were injected in the HPLC column (Kromasil® 100-5 phenyl, 250 × 4.6mm), thermostated at 30°C. The mobile phase, a mixture of acetonitrile and acetic acid 1% + triethylamine 0.1% (35:65), was flushed at 1 ml min-1 with an isocratic pump (mod. 1515; Waters Corp, Milford, MA). The effluent was analyzed with a fluorescence detector (mod. 2487; Waters Corp, Milford, MA) with excitation and emission wavelengths set at 256 and 380 nm, respectively. The retention times of 4.5 and 5 min were associated with heteroduplex (2988G/A) and homoduplex (2988A) profiles, detecting wild-type and mutant alleles, respectively. Variant genotypes were verified by direct Sanger sequencing (CEQ2000XL, Beckman Coulter). Full CYP2D6 deletion (CYP2D6*5) analysis was conducted with a long-range PCR using the DyNAzyme II DNA Polymerase kit (Thermo Fisher Scientific) according to the manufacturer’s instructions and a 1% agarose gel run, as described by Sistonen et al.20

The CYP2D6 activity score was calculated according to the Clinical Pharmacogenetic Implementation Consortium and Dutch Pharmacogenetics Working Group criteria, which assigned scores of 0, 0.25, 0.5, 1, or 2 to each allele based on their relative activity compared with the wild type (=1), as follows: *3, *4, *5, *6 = 0; *10 = 0.25; *9, *41 = 0.5; no variant alleles = 1; and *1 × 2N = 2. The sum of the activity scores for each allele (AS) was translated into the following CYP2D6 phenotypes: ultrarapid metabolizers (UM), AS > 2.25; normal metabolizers (NM), 1.25 ≤ AS ≤ 2.25; intermediate metabolizers (IM), 0 < AS < 1.25; poor metabolizers (PM), AS = 0.

Allele *41 (G2988A, rs28371725) was detected using denaturing HPLC. Specific primers were designed with Primer3 software and confirmed with Human Genome Browser in silico tools as follows: fw 5′-GAGCCCATCTGGGAAACAGT-3′ and rv 5′-CCTCCTATGTTGGAGGAGTC-3′. PCR was performed with 1U of Hot Start DNA polymerase AmpliTaq Gold (Applied Biosystems) in a final volume of 50 μl; the annealing temperature was 58°C, for 38 cycles. The optimal melting temperatures for SNP detection was experimentally determined as 62.8°C. Each sample was run alone and with a plasmid positive control (containing the CYP2D6 2988A variant, obtained with the QuickChange Site-Directed Mutagenesis kit by Agilent Technologies) for 8 min with a gradient mobile phase consisting of Buffers A (triethyl ammonium acetate) and B (triethyl ammonium acetate and acetonitrile) at a flow rate of 0.9 ml min-1. Retention times of 4.5 and 5 min were associated with heteroduplex (2988G/A) and homoduplex (2988A) profiles, detecting wild-type and mutant alleles, respectively. Variant genotypes were verified by direct Sanger sequencing (CEQ2000XL, Beckman Coulter). Full CYP2D6 deletion (CYP2D6*5) analysis was conducted with a long-range PCR using the DyNAzyme II DNA Polymerase kit (Thermo Fisher Scientific) according to the manufacturer's instructions and a 1% agarose gel run, as described by Sistonen et al.20
were linear with a coefficient of determination \( R^2 \) always > 0.99. Precision, accuracy, and quantification limits are shown in Appendix 1.

2.5  |  CYP2D6 phenotyping procedure

The logarithm of the ratio of urinary DM to DX molar concentrations \[\log(\text{DM}/\text{DX})\] was taken as a measure of CYP2D6 activity. Patients were classified as poor metabolizers (PM), intermediate metabolizers (IM), extensive metabolizers (NM), or ultra-rapid metabolizers (UM) according to their log(DM/DX) ratio, as follows: PM \( \geq -0.52 \); IM \(-1.52 < \leq -1.52 \); NM, \(-1.52 < \leq -2.52 \); UM \(-2.52 < \).\)

Since ND-TAM is metabolized to ENDO by the cytochrome CYP2D6, the logarithm of the ratio of ND-TAM to ENDO plasma concentrations \[\log(\text{ND-TAM}/\text{ENDO})\] was considered another independent measure of CYP2D6 activity.

2.6  |  Statistical analysis

In the tables, continuous variables are presented as means \( \pm \) standard deviations (unless otherwise stated), and categorical variables as absolute numbers and percentages.

Continuous variables with a normal distribution were compared with Student's t test. One-way ANOVA was used for comparing more than two independent groups, followed by Bonferroni post-hoc tests for pairwise comparisons, and the test for linear trend, as needed. Two-way ANOVA was used to compare repeated measures from the same patient. The homoscedasticity assumption was verified with the Bartlett and Levene test. Equivalent non-parametric tests (the Mann-Whitney U, Kruskal-Wallis and Friedman tests) were used whenever applicability conditions were not met. Categorical data frequencies were examined using Pearson's chi-square and Fisher's exact test, as appropriate.

ENDOss was calculated as the mean of ENDO concentrations at 4 and 8 months, if both measurements were available, or at 4 months otherwise. A log-transformation was applied (log-ENDOss) to achieve a normal distribution of ENDOss.

The following independent variables were used in the regression analyses: age (years), body weight (kg), body surface area (BSA; calculated with the Haycock formulae, m\(^2\)), body mass index (BMI; kg m\(^{-2}\)), log(DM/DX), concomitant use of CYP2D6 weak inhibitors, and CYP2D6 activity score. CYP2D6 activity scores were translated into four phenotypes (UM, NM, IM, PM), according to the updated CPIC guidelines.\(^{22}\) Since only one patient was classified as UM (genotype 1 \( \times \) 2N*1), she was included in the NM group.

First, univariable linear regression analyses were run, taking one independent variable at a time. Then, a stepwise multivariable forward regression was conducted (\( P < .05 \) for variable inclusion, and \( P < .15 \) for variable removal) to select the best log-ENDOss prediction model. Multicollinearity was checked using the tolerance and the variance inflation factor (VIF); variables with a tolerance <0.4 (VIF > 2.5) were discarded from the analysis.

Possible confounding effects were investigated with all variables excluded by the stepwise selection. Residuals analysis was performed to examine the models' goodness of fit and adherence to the regression assumptions. The validity of the final model was assessed by measuring the \( R^2 \) coefficient and the mean absolute and percentage errors (MAE and MAPE) of the ENDOss predicted.

Pearson's correlation coefficients (\( r \)) were used to test the relationship between log(DM/DX) and log-ENDOss, and between log(DM/DX) and log(NDT/ENDO).

A receiver operating characteristics (ROC) analysis was used to identify the threshold for the log(DM/DX) ratio associated with ENDOss \(< 5.97 \) ng ml\(^{-1}\), and the area under the ROC curve (AUC) was estimated.

All statistical analyses were performed using STATA SE, version 12.1 (Stata Statistical Software, College Station, TX: StataCorp LP), setting the level of significance at 0.05.

3  |  RESULTS

3.1  |  Patients' characteristics

Of the population of 203 women, only 164 were suitable for multivariable regression analyses as all the independent variables were available. Table 1 summarizes patients' characteristics for the whole group and for the regression group. No patients were taking strong CYP2D6 inhibitors, while 12 in the whole group and 9 in the regression group were taking weak inhibitors (citalopram, sertraline, duloxetine, venlafaxine). There were no statistically significant differences between the variables considered in the two groups, except for age (\( P = .0083 \)), and menopausal status (\( P = .023 \)).

3.2  |  ENDO, 4OH-TAM, ND-TAM and TAM plasma concentrations

Figure 2 shows the median plasma concentrations (box and whisker plots) of all compounds during the follow-up. All measures showed a wide inter-subject variability.

Four separate two-way repeated-measures ANOVAs were run to identify any differences in the concentrations of the four compounds at the different times (1, 4 and 8 months). The results showed that mean ENDO, ND-TAM and TAM concentrations rose significantly from the first to the fourth month, then remained stable (for all three compounds, comparisons were significant [\( P < .0001 \)] for month 1 vs month 4, and for month 1 vs month 8), while 4OH-TAM concentrations remained stable throughout the observation period. The mean absolute difference in ENDO concentrations between month 4 and month 8 was \( 2.5 \pm 2.6 \) ng ml\(^{-1}\) (mean change: +8%, n.s.).
TABLE 1  Patients’ characteristics in the whole sample and in the group for regression analysis

| Variable                      | Whole sample (N = 203) | Sample for regression analysis (N = 164) |
|-------------------------------|------------------------|-----------------------------------------|
| Age (years), mean ± SD [range]| 56.2 ± 11.7 [29-89]    | 57.2 ± 11.2 [33-89]                     |
| Body weight (kg), mean ± SD [range] | 67.4 ± 13.5 [42 - 115] | 67.8 ± 13.9 [43-115]                    |
| Body surface area (m²), mean ± SD [range] | 1.75 ± 0.20 [1.33-2.44] | 1.75 ± 0.20 [1.36-2.44]                |
| BMI (kg m⁻²), mean ± SD [range]   | 25.7 ± 5.0 [15.8-42.9] | 25.9 ± 5.1 [15.8-42.9]                  |
| In menopause, n (%)             |                        |                                         |
| Yes                           | 147 (73%)              | 126 (77%)                               |
| No                            | 53 (27%)               | 38 (23%)                                |
| Weak inhibitor use, n (%)      |                        |                                         |
| Yes                           | 12 (6%)                | 9 (5%)                                  |
| No                            | 191 (94%)              | 155 (95%)                               |
| ENDO concentration (ng ml⁻¹)  | 8.05 ± 4.85 [1.20-27.00] | 8.13 ± 5.05 [1.20-27.00]                |
| after 1 month, mean ± SD [range] |                        |                                         |
| ENDO concentration (ng ml⁻¹)  | 10.57 ± 6.83 [1.60-40.41] | 10.69 ± 6.88 [1.60-40.41]              |
| in steady state, mean ± SD [range] |                        |                                         |
| Log(DM/DX), mean ± SD [range] | -1.59 ± 0.89 [-3.08-1.39] | -1.61 ± 0.87 [-3.08-1.39]              |
| CYP2D6 phenotype, n (%)       |                        |                                         |
| PM                            | 15 (8.1%)              | 14 (8.6%)                               |
| IM                            | 64 (34.2%)             | 53 (32.3%)                              |
| NM                            | 107 (57.2%)            | 96 (58.5%)                              |
| UM                            | 1 (0.5%)               | 1 (0.6%)                                |

Abbreviations: BMI, Body Mass Index; DM, dextromethorphan; DX, dextrophan; ENDO, Z-endoxifen plasma concentrations; IM, intermediate metabolizer; NM, normal metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.

Figure 2  Box and whisker plots (circles are outliers) of plasma concentrations of endoxifen (ENDO), 4OH-tamoxifen (4OH-TAM), N-desmethyl-tamoxifen (ND-TAM), and tamoxifen (TAM) after 1, 4, and 8 months. Asterisks indicate significant differences from values at 1 month.

3.3 | Log(DM/DX) and CYP2D6 phenotype

One-way ANOVA followed by testing for linear trends showed a significant difference in the mean log(DM/DX) values across groups identified by CYP2D6 phenotype (P < .0001) (Figure 3). These log(DM/DX) values varied considerably within each group, however, indicating that CYP2D6 activity inferred from CYP2D6 genotype cannot accurately predict the phenotype. In fact, 34% of patients classified according to the CYP2D6 genotype did not match the phenotype assessed with the log (DM/DX) classification system.¹⁰

3.4 | ENDOss, Log(DM/DX), and CYP2D6 phenotype

Log-ENDOss correlated inversely with log(DM/DX) (r = 0.63; P < .0001) (Figure 4, panel a) and one-way ANOVA showed a rising trend of log-ENDOss in parallel with CYP2D6 phenotype (significant comparisons: PM vs IM, NM + UM; and IM vs NM + UM; P < .0001) (Figure 4, panel b). Similar correlations emerged for steady-state 4OH-TAM concentrations (4OH-TAMss), whereas steady-state DM-TAM levels (DM-TAMss) correlated directly with log(DM/DX), and inversely with CYP2D6 phenotype (data not shown). TAM concentrations did not correlate with CYP2D6 activity markers.

Of note, urinary log(DM/DX) correlated significantly with plasma log(ND-TAM/ENDO) at 1 month (r = 0.70; P < .0001), indicating that both ratios reflect CYP2D6 metabolic activity (Figure 5).
Considering the ENDOss concentration of 5.97 ng ml\(^{-1}\) indicated by Madlensky et al.\(^4\) as the threshold for a favorable clinical outcome, our data show that all patients with an activity score of 0 had sub-therapeutic ENDO levels (Figure 4, panel b). ROC analysis identified a cut-off for log(DM/DX) of \(-1.445\) beyond which most patients had ENDOss \(\leq 5.97\) ng ml\(^{-1}\) (0.776 in log-scale), with 89% sensitivity and 67% specificity (AUC = 0.82, 95% confidence interval: 0.74-0.91, \(P < .001\)) (Figure 4, panel a).

### 3.5 Univariable and multivariable analyses

On univariable linear regression, the following variables significantly predicted log-ENDOss: log(DM/DX) (\(R^2 = 0.39\)); CYP2D6 phenotype (\(R^2 = 0.37\)); weak inhibitor use (\(R^2 = 0.055\)); and body surface area (\(R^2 = 0.032\)) (Table 2). After multicollinearity checking, body surface area was discarded from subsequent analyses due to its collinearity with BMI.

The stepwise multivariable regression analysis identified log(DM/DX), patient’s age, weak inhibitor use, and CYP2D6 phenotype as significant independent predictors of log-ENDOss, ruling out BMI:

\[
\log - \text{ENDOss} = 0.162 - \log (\text{DM/DX}) \times 0.170 + \text{age} \times 0.0063 - \text{weak inhibitor use} \times 0.250 + \text{IM} \times 0.105 + (\text{NM} + \text{UM}) \times 0.210
\]

\(R^2 = 0.510;\) MAE = 0.16 ng ml\(^{-1}\); MAPE = 21.2%

Log(DM/DX) and CYP2D6 phenotype were collinear so they were alternately removed from the regression to see which model performed better:

\[
\log - \text{ENDOss} = 0.218 + \text{IM} \times 0.444 + (\text{NM} + \text{UM}) \times 0.608 + \text{age} \times 0.0041 - \text{weak inhibitor use} \times 0.265
\]

\(R^2 = 0.478;\) MAE = 0.16 ng ml\(^{-1}\); MAPE = 21.2%

Equation 2, which included log(DM/DX), yielded a higher \(R^2\) than Equation 3, with small changes in MAE and MAPE.

To translate these models into clinically relevant information, linear ENDOss were predicted for each patient by transforming the results of Equations 1-3 into the corresponding anti-logarithms. Tables 3-5 show the partial variances (\(R^2\)) explained by each variable in Equation 1, 2, and 3. Table 6 shows the MAEs and MAPE (± SD, range) of the ENDOss obtained with each equation.
4 DISCUSSION

This study showed that the co-variables log(DM/DX), age and weak inhibitor use, and CYP2D6 phenotype correlated significantly with log-ENDOss on multiple regression analysis, explaining 51.0% of log-ENDOss variability. The best predictor was log(DM/DX) (partial $R^2 = 0.39$), with the contributions of age (partial $R^2 = 0.051$), weak inhibitor use (partial $R^2 = 0.035$), and CYP2D6 phenotype (partial $R^2 = 0.032$) decreasingly important (Table 3). When CYP2D6 phenotype was removed from the regression, the overall $R^2$ was marginally lower (0.48), whereas removing log(DM/DX) resulted in a greater decrease in $R^2$ (0.41).

These results were not unexpected because the expression of CYP2D6 activity is controlled by several nongenetic factors, which matter especially in patients with intermediate-to-fast genotypes. In fact, 34% of IMs, NMs and UMs did not match the phenotype derived from log(DM/DX), whereas only 1 of 14 PMs was classified as IM by log(DM/DX) (Figure 3).

Other potential limitations of the activity score system are that not all CYP2D6 variant alleles are routinely genotyped and that the scoring criteria may change as new information becomes available. Indeed, the score has been challenged by Schroth et al, who showed that downgrading CYP2D6*10 activity score from 0.5 to 0.25 improved ENDOss prediction, so new guidelines have recently been updated. In short, phenoconversion and activity score misclassification can both weaken the predictive power of CYP2D6 genotype. On the other hand, genotype is stable for life, whereas DM levels may change due to intervening, non-genetic factors (Table 7).

Several clinical studies investigated the correlation between CYP2D6 genotype-derived activity and ENDOss, using various methods and phenotyping criteria, and with mixed results. In general, individuals labelled as PMs have significantly lower ENDOss.

**Table 3** $\beta$ Coefficients and significance levels of variables significantly associated with log-transformed ENDOss, by multivariable regression analysis (Equation 1)

| Variable          | $\beta$ Coefficient (95% CI) | P-value | Partial $R^2$ |
|-------------------|-------------------------------|---------|---------------|
| Intercept         | 0.162 (-0.047 to 0.371)       | .127    | --            |
| Log(DM/DX)        | -0.170 (-0.228 to -0.111)     | <.0001  | 39.25         |
| Age (years)       | 0.0063 (0.003 to 0.009)       | <.0001  | 5.13          |
| Weak inhibitor use| -0.250 (-0.389 to -0.110)     | .001    | 3.46          |
| CYP2D6 phenotype  |                              |         |               |
| IM                | 0.105 (-0.064 to 0.275)       | .221    | 3.17          |
| NM + UM           | 0.210 (0.030 to 0.391)        | .023    |               |

Note: Total $R^2$: 51.01; MAE = 0.16 ng ml⁻¹; MAPE = 19.94%.

**Table 4** $\beta$ Coefficients and significance levels of variables significantly associated with log-transformed ENDOss, after substituting Log(DM/DX) for CYP2D6 phenotype in multivariable regression analysis (Equation 2)

| Variable          | $\beta$ Coefficient (95% CI) | P-value | Partial $R^2$ |
|-------------------|-------------------------------|---------|---------------|
| Intercept         | 0.225 (0.023 to 0.427)        | .030    | --            |
| Log(DM/DX)        | -0.223 (-0.262 to -0.184)     | <.0001  | 39.25         |
| Age (years)       | 0.0065 (0.003 to 0.009)       | <.0001  | 5.13          |
| Weak inhibitor use| -0.235 (-0.377 to -0.092)     | .001    | 3.46          |

Note: Total $R^2$: 47.84; MAE = 0.16 ng ml⁻¹; MAPE = 21.19%.

**Table 2** Intercepts, $\beta$ coefficients and significance levels obtained by univariable regression analyses

| Variables          | Intercept (95% CI) | $\beta$ Coefficients (95% CI) | P-value | $R^2$ |
|--------------------|-------------------|------------------------------|---------|-------|
| Log(DM/DX)         | 0.61 (0.54 to 0.68) | -0.21 (-0.25 to -0.17)       | <.0001  | 39.25 |
| CYP2D6 phenotype   | 0.44 (0.32 to 0.56) | 0.46 (0.32 to 0.60)          | <.0001  | 34.73 |
|                    | IM                | 0.60 (0.47 to 0.73)          | <.0001  |       |
|                    | NM + UM           | 0.96 (0.91 to 1.00)          | -0.29 (-0.48 to -0.11) | .002 | 5.53 |
| Weak inhibitor use | 1.39 (1.00 to 1.77) | -0.25 (-0.47 to -0.037)      | .022    | 3.19  |
| Body surface area  | 1.05 (0.83 to 1.28) | -0.0043 (-0.013 to 0.004)    | ns (.33) | 0.59  |
| BMI (kg m⁻²)       | 0.89 (0.66 to 1.12) | 0.0009 (-0.003 to 0.005)     | ns (.65) | 0.12  |
| Age, (years)       |                   |                              |         |       |
than EMs.24 Only four studies phenotyped CYP2D6 activity with the dextromethorphan test, using different experimental approaches. De Graan et al.25 calculated the area under the concentration-time curve of DM during a 6-hour interval in 40 women, finding it correlated inversely with trough ENDOss (r = −0.72). Opdam et al.,26 and Safgren et al.27 used the $^{13}$C-DM breath test, measuring the expired $^{13}$CO$_2$ as an index of DM demethylation: they reported significant correlations between the changes in $^{13}$CO$_2$ and ENDOss, with r values of 0.56 (n = 77) and 0.69 (n = 65), respectively. Antunes et al.28 simultaneously phenotyped CYP2D6 and CYP3A4 activities in 116 patients by calculating the [DM]/[DX] and [omeprazole]/[omeprazole sulphone] metabolic ratios in a single plasma sample obtained 3 hours after oral administration of DM and omeprazole. They found that the [DM]/[DX] ratio was associated with ENDOss (r = −0.52), but the [omeprazole]/[omeprazole sulphone] ratio was not.

Incidentally, our phenotyping method based on the urinary log(DM/DX) ratio was validated by comparison with the reference debrisoquine test 10 and found to correlate with the partial metabolic clearance of DM to DX.13 A good correlation was also demonstrated in our population between urinary log(DM/DX) ratio and plasma log(ND-TAM/ENDO) ratio, which is another measure of CYP2D6 activity (Figure 5). Notably, Saladores et al.5 reported that the ND-TAM/ENDO metabolic ratio correlated significantly with the RFS hazard ratio (HR) on multivariable Cox’s regression.

Efforts to predict ENDOss may be justified to the extent that they can forecast treatment outcomes. Conflicting data are available for now. Madlensky et al.,4 and Saladores et al.5 documented better outcomes when ENDOss plasma concentrations exceeded 14-16 nM (5.2-5.97 ng ml-1). It should be noted that both studies included women with early-stage breast cancer and Saladores’s study only considered premenopausal patients. Another study on a small sample (n = 86) with a long median follow-up (13.8 years) found long-term overall survival worse for patients with ENDOss concentrations <9 nM or 4OH-TAM <3.26 nM.29 The CYP TAM study showed that neither CYP2D6 genotypes nor ENDOss levels were associated with RFS in 667 women taking TAM (20 mg q.d.) 30 for a median of 2.5 years (median follow-up 6.4 years), then shifted to an aromatase inhibitor in 66% of cases. Given the long time to recurrence of breast cancer, the short duration of therapy and follow-up may explain the negative results of this study. In addition, the HR used to estimate the sample size was probably too high as well (HR = 2), compared with the HR of 1.4 found significant in Madlensky's study. Two other studies found no association between ENDOss and clinical endpoints.31,32 All patients had advanced breast cancer, however, and most of them were post-menopausal. The conflicting results may therefore be due to differences in patient selection (cancer stage, menopausal status) and study design (duration of therapy and follow-up, sample size calculation). In agreement with this hypothesis, Margolin et al.33 reported that CYP2D6 genotypes with low activity scores (presumably associated with

### TABLE 5

| Variable                          | β Coefficient (95% CI) | P-value  | Partial $R^2$ |
|----------------------------------|------------------------|----------|---------------|
| Intercept                        | 0.218 (-0.009 to 0.445)| .060     | —             |
| CYP2D6 phenotype                 |                        |          |               |
| IM                               | 0.444 (0.310 to 0.577) | <.0001   | 34.73         |
| NM + UM                          | 0.608 (0.480 to 0.735) | <.0001   |               |
| Weak inhibitor use               | -0.265 (-0.418 to -0.112)| .001     | 3.47          |
| Age (years)                      | 0.0041 (0.001 to 0.007)| .010     | 1.86          |

Note: Total $R^2$: 40.96; MAE = 0.17 ng ml-1; MAPE = 21.79%.

### TABLE 6

| Equations (n°) | MAE (ng ml-1) | MAPE (%) |
|----------------|---------------|----------|
| 1              | 3.76          | 39.74    |
| 2              | 3.89          | 41.84    |
| 3              | 4.07          | 43.53    |

### TABLE 7

| PROs                                      | CONs                                      |
|-------------------------------------------|-------------------------------------------|
| Log(DM/DX) metabolic ratio                | The influence of non-genetic factors (drug-drug interactions, co-morbidities, pregnancy, etc) is included                      |
|                                           | Results may change over time               |
|                                           | Renal function and urine pH may affect the log(DM/DX) metabolic ratio |
|                                           | Time-consuming (urine collection, drug/metabolite assay) |
| CYP2D6 phenotype (CPIC)                   | Single blood sample required               |
|                                           | Not all CYP2D6 variants are routinely assessed |
|                                           | The activity score attributed to each variant allele may be challenged |
|                                           | Phenoconversion can bias the results |

GUSELLA ET AL. | 8 of 11
low ENDO levels) had negative outcomes mainly in pre-menopausal women, and suggested that higher estrogen levels require a more efficient TAM bio-activation. In the same vein, advanced cancer stages may be less responsive to anti-estrogen therapy, thus yielding a flat correlation between ENDOss and clinical outcomes.

While waiting for more conclusive results, it has been suggested that TAM dose be adjusted according to ENDOss rather than CYP2D6 geno-phenotype. In line with this view, Fox et al increased the TAM doses in 68 of 122 patients based on their individual ENDOss levels. Following this dose escalation, the percentage of patients with ENDOss >15 nM rose from 76% to 96% and the percentage of those with ENDOss >30 nM from 34% to 76%. Two other studies showed that TAM dose escalation from 20 mg to 40 mg q.d. did not increase the frequency or severity of side effects.

This approach seems appealing, but means that TAM dosage can only be adjusted after 2-3 months of therapy, when a steady state has been reached.

An alternative strategy—suggested by Hertz and Rae, and supported by our results—could reduce the time it takes to optimize the TAM dosage. Before starting treatment, we can compute patients’ log(DM/DX) or CYP2D6 phenotype (depending on the method available at the point of care), and predict their log-ENDOss using Equation 2 or Equation 3, then obtain their ENDOss by calculating the anti-logarithm.

Whatever the method used, patients whose predicted ENDOss concentration is lower than the threshold of 5.97 ng mL-1 should start therapy with doses >20 mg. Assuming a linear dose-concentration relationship, the dose should be increased by the threshold-to-predicted-concentration ratio and rounded up to 30 or 40 mg. Should higher (off-label) doses be required, aromatase inhibitors may be an alternative option, since little is known about the long-term safety of higher doses of TAM.

Adequately-powered prospective trials are obviously needed to test this strategy.

Our study has some limitations. First, we assumed that all patients adhered to their TAM treatment. Though we could not prove as much, it is reasonable to assume a good compliance at the start of the therapy. The long half-lives of TAM and its metabolites should also guarantee stable ENDO concentrations even if a TAM dose is missed occasionally. Second, we did not genotype all the known CYP2D6 variants, but only those most common in Caucasians, so our results cannot be extended to other ethnicities. Third, ENDOss are reportedly 20% lower in winter than the mean year-round levels. Our study covered a period of 8 months, so ENDOss may have been influenced by seasonal changes. That said, a post-hoc analysis of our data (not shown) found no differences in ENDOss measured in January-March versus July-September. Fourth, the results of urinary DM testing may be affected by changes in urinary pH and renal function, thus leading to misphenotyping CYP2D6. Although we cannot exclude this possibility, such a bias can be minimized by collecting urine over a long period (10 hours), as we did. The log(DM/DX) ratio also correlated strongly with the log(ND-TAM/ENDO), which more closely reflects ENDO production by CYP2D6.

5 | CONCLUSIONS

Our study found that phenotyping CYP2D6 activity by means of a urinary DM test is the single best predictor of ENDOss. A model including log(DM/DX), patient’s age, and use of CYP2D6 inhibitors has an acceptable predictive performance, and could be used as an alternative to genotyping tests. Despite some uncertainty regarding the optimal ENDOss, a therapeutic approach that aims at personalizing TAM dosage early on is worth testing in a prospective trial.

ACKNOWLEDGEMENTS

This research was funded by grants from the Regione Veneto (Ricerca Finalizzata 2009), LILT - Rovigo (grants 2012-2020), and the Department of Medicine at the University of Padova (DOR 2017).

CONFLICT OF INTERESTS

None of the authors have any competing interests to disclose.

AUTHORS’ CONTRIBUTIONS

MG, FP, NM, and RP contributed to study conception and design. LB, GDR, CF, YM, CB, DDC, APF, ST, EC, AB, CM, and RS contributed to data acquisition. MG, BC, NM, and RP contributed to data analysis and interpretation. MG, BC, and RP contributed to manuscript drafting. MG, FP, BC, CO, NM, and RP contributed to manuscript revision.

DATA AVAILABILITY STATEMENT

The data analyzed in this study are available from the corresponding author on reasonable request.

ORCID

Milena Gusella https://orcid.org/0000-0002-6257-0282
Barbara Corso https://orcid.org/0000-0002-0684-9078

REFERENCES

1. Johnson MD, Zuo H, Lee K-H, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004;85:151-159.
2. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005;55:471-478.
3. de Vries Schultink AHM, Alexi X, van Werkhoven E, et al. Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome. Breast Cancer Res Treat. 2017;161:567-574.
4. Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89:718-725.
5. Saladores P, Mürdter T, Eccles D, et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2015;15:84-94.

6. de Vries Schultink AHM, Huitema ADR, Beijnen JH. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy. Breast. 2018;42:38-40.

7. Binkhorst L, Mathijssen RH, Jager A, van Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev. 2015;41:289-299.

8. Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H. CYP2D6 genotype predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2015;15:84-94.

9. Schmid B, Bircher J, Preisig R, Küpfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther. 1985;38:618-624.

10. Coen EA, Reiner AS, et al. CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res. 2018;20:149.

11. CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther. 1996;60:295-307.

12. Shah RR, Smith RL. Br J Clin Pharmacol. Addressing phenocversion: the Achilles’ heel of personalized medicine. 2015;79:222-240.

13. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791:245-253.

14. Brooks JD, Comen EA, Fox P, Balleine RL, Lee C, et al. Dose escalation of tamoxifen in patients with diminished CYP2D6 activity: a retrospective matched case-control study. Neuropsychobiology. 2018;9:446-452.

15. Levo A, Koski A, Ojanperä I, Vuori E, Sajantila A. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci Int. 2003;135:9-15.

16. Kobylecki CJ, Jakobsen KD, Hansen T, Jakobsen IV, Rasmussen HB, Werge T. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology. 2009;59:222-226.

17. Al-Dosari MS, Al-Jenobi FI, Alkhafy KM, et al. High prevalence of CYP2D6*41 (G2988A) allele in Saudi Arabsian. Environ Toxicol Pharmacol. 2013;36:1063-1067.

18. http://primer3.ut.ee. Accessed October 10, 2019

19. Sistonen J, Fuselli S, Levo A, Sajantila A. CYP2D6 genotyping by a multiplex primer extension reaction.

20. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13:116-124.

21. Flores-Perez J, Flores-Perez C, Juarez-Olguin H, Lares-Assef I, Sosa-Marcias M. Determination of dextromethorphan and dextrophan in human urine by high performance liquid chromatography for pharmacogenetic investigations. Chromatographia. 2004;59:481-485.

22. Schroth W, Winter S, Mürdter T, et al. Prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen. Front Pharmacol. 2017;8:article 582.

23. Hwang GS, Bhat R, Crutchley RD, Trivedi MV. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. Pharmacogenomics J. 2018;18:201-208.

24. de Graan A-J, Teunissen SF, de Vos FYFL, et al. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol. 2011;29:3240-3246.

25. Opdam FL, Dezentjé VO, den Hartigh J, et al. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. Cancer Chemother Pharmacol. 2013;71:593-601.

26. Saagbre SL, Suman VJ, Kosel ML, et al. Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen. Pharmacogenet Genomics. 2015;25:157-163.

27. Antunes MV, da Fontoura Titt MD, de Oliveira V, et al. Influence of CYP2D6 and CYP3A4 phenotypes, drug Interactions, and vitamin D status on tamoxifen biotransformation. Ther Drug Monit. 2015;37:733-744.

28. Halland T, Henne N, Bifulco E, et al. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res. 2017;19:125.

29. Sanchez-Spitman A, Dezentjé V, Swen J, et al. Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study. J Clin Oncol. 2019;37:636-646.

30. Neven P, Jongen L, Lintemans A, et al. Tamoxifen metabolism and efficacy in breast cancer: a prospective multicenter trial. Clin Cancer Res. 2018;24:2312-2318.

31. Tamura K, Imamura CK, Takano T, et al. CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer (TARGET-1): a randomized, open-label, phase ii study. J Clin Oncol. 2020;38:558-566.

32. Dezentjé VO, Gelderblom H, et al. Tamoxifen and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics. 2013;14:613-622.

33. Groenland SL, van Nuland M, Verheijen RB, et al. Therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Clin Pharmacokinet. 2019;58:299-308.

34. Hennig EE, Piatkowska M, Karczmarzki J, et al. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer. BMC Cancer. 2015;15:570.

35. Fox P, Balleine RL, Lee C, et al. Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring-the TADE Study. Clin Cancer Res. 2016;22:3164-3171.

36. Dezentjé VO, Opdam FL, Gelderblom H, et al. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. Breast Cancer Res Treat. 2015;153:583-590.

37. Hertz DL, Deal A, Ibrahim JG, et al. Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity. Oncologist. 2016;21:795-803.

38. Hertz DL, Rae JM. Individualized tamoxifen dose escalation: confirmation of feasibility, question of utility. Clin Cancer Res. 2016;22:3121-3123.

39. Trent WA, Gong YI, Ding B, et al. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat. 2013;139:95-105.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.
How to cite this article: Gusella M, Pasini F, Corso B, et al; Italian TAM Group. Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable? Pharmacol Res Perspect. 2020;e00646. https://doi.org/10.1002/prp2.646

APPENDIX

The Italian TAM Study Group

The following people contributed to this study:

Silvia Angelini1, Susanne Baier10, Carmen Barile4, Franco Bassan20, Emanuela Beda13, Laura Bertolaso4, Andrea Bonetti16, Lucia Borgato3, Antonella Brunello1, Maria Paola Cecchini14, Barbara Corso21, Giorgio Crepaldi3, Elisabetta Cretella19, Donatella Da Corte Z.7, Cristina DeAlisi10, Giovanni DeRosa12, Emilia Durante16, Cristina Falci2, Adolfo Favaretto5, Elena Fiorio7, Anna Paola Fraccon8, Lara Furini12, Alice Giacobino7, Tommaso Giarratano2, Carlo Alberto Giorgi3, Filippo Greco15, Milena Gusella4, Alessandro Inno4, Micaela Lenotti7, Maria Rita Lusso10, Marta Mandarà19, Daniela Menon4, Federica Merlin19, Marta Mion13, Nadia Minicuci21, Yasmine Modena4, Caterina Modonesi14, Linda Nicolardi20, Cristina Oliani4, Roberto Padrini22, Dario Palleschi5, Felice Pasini6, Maria Cristina Pegoraro7, Elena Pellegrinelli4, Elisa Perfetti9, Elisa Pezzolo6, Paolo Piacentini14, Valentina Polo7, Concetta Raiti18, Elvira Rampello19, Ilaria Rocco21, Romana Segati15, Elena Seles3, Mariella Sorarù13, Laura Stievano4, Ottaviano Tomassi18, Silvia Tosò8, Francesca Vastola14, Emanuela Vattemi10, Alberto Zaniboni11, Marta Zaninelli12

1Oncology Unit 1, Istituto Oncologico Veneto (IOV), IRCCS Padova, Italy; 2Oncology Unit 2, Istituto Oncologico Veneto (IOV), IRCCS Padova, Italy; 3Oncology Unit, Ospedale degli Infermi, Biella, Italy; 4Oncology Unit, Ospedale di Rovigo, AULSS5 Polesana, Italy; 5Oncology Unit, Ospedale di Treviso, AULSS2 Marca Trevigiana, Italy; 6Oncology Unit, Casa di Cura Pederzoli, Peschiera del Garda, Italy; 7Oncology Unit, AOU Verona, Italy; 8Oncology Unit, Ospedale di Adria, AULSS5 Polesana, Italy; 9Oncology Unit, Ospedale di Belluno, AULSS1 Dolomiti, Italy; 10Oncology Unit, Ospedale di Bolzano, Az. Sanitaria dell’Alto Adige, Italy; 11Oncology Unit, Fondazione Poliambulanza, Brescia, Italy; 12Oncology Unit Ospedale di Villafranca, AULSS9 Scaligera, Italy; 13Oncology Unit, Ospedale di Camposampiero e Cittadella, AULSS6 Euganea, Italy; 14Oncology Unit, Ospedali Riuniti Padova Sud, AULSS6 Euganea, Italy; 15Oncology Unit, Ospedale di Feltre, AULSS1 Dolomiti, Italy; 16Oncology Unit, Ospedale di Legnago, AULSS 9 Scaligera, Italy; 17Oncology Unit, Ospedale di Montecchio Maggiore, AULSS8 Berica, Italy; 18Oncology Unit, Ospedale di S Dona’, AULSS4 Veneto Orientale, Italy; 19Oncology Unit, Ospedale di San Bonifacio, AULSS9 Scaligera, Italy; 20Oncology Unit, Ospedale Altovicentino, AULSS 7 Pedemontana, Italy; 21National Research Council, Neuroscience Institute, Padova, Italy; 22Clinical Pharmacology Unit of the Department of Medicine (DIMED), University of Padova, Padova, Italy